CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612993 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Woosol Chris Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National R&D Program for Cancer Control through the National Cancer Center (NCC), National Research Foundation of Korea (NRF) grants by the Korean Government, Ministry of Science and ICT (MSIT), National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer with a poor prognosis and low survival rates. The prognostic and predictive biomarkers of PDAC are still largely unknown. The receptor CD74 was recently identified as a regulator of oncogenic properties in various cancers. However, the precise molecular mechanism of CD74 action in PDAC remains little understood. We investigated the role of CD74 by silencing CD74 in the pancreatic cancer cell line Capan-1. CD74 knockdown led to reductions in cell proliferation, migration, and invasion and increased apoptosis. Moreover, silencing CD74 resulted in the decreased expression and secretion of S100A8 and S100A9. An indirect co-culture of fibroblasts and tumor cells revealed that fibroblasts exposed to conditioned media from CD74 knockdown cells exhibited a reduced expression of inflammatory cytokines, suggesting a role of CD74 in influencing cytokine secretion in the tumor microenvironment. Overall, our study provides valuable insights into the critical role of CD74 in regulating the oncogenic properties of pancreatic cancer cells and its influence on the expression and secretion of S100A8 and S100A9. Taken together, these findings indicate CD74 as a potential diagnostic biomarker and therapeutic target for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
ORCID-Profile: Sungsoon Fang, Joon Seong Park
Förderung
- National R&D Program for Cancer Control through the National Cancer Center (NCC)
- National Research Foundation of Korea (NRF) grants by the Korean Government, Ministry of Science and ICT (MSIT)
- National Research Foundation of Korea (NRF)
- National Cancer Center (NCC)
Zitieren
APA
Hong, W. C., Lee, D. E., Kang, H. W., Kim, M. J., Kim, M., Kim, J. H., Fang, S., Kim, H. J., & Park, J. S. (2023). CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612993
Vancouver
Hong WC, Lee DE, Kang HW, Kim MJ, Kim M, Kim JH, et al. CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612993
BibTeX
@article{Hong2023,
author = {Hong, Woosol Chris and Lee, Da Eun and Kang, Hyeon Woong and Kim, Myeong Jin and Kim, Minsoo and Kim, Ju Hyun and Fang, Sungsoon and Kim, Hyo Jung and Park, Joon Seong},
title = {CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612993}
}
EUVIMED